The C1GALT1C1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 hepatic adenocarcinoma cell line. This product features targeted disruption of the C1GALT1C1 gene, which encodes the Cosmc molecular chaperone essential for the folding and stability of C1GALT1 (T-synthase), the glycosyltransferase responsible for core 1 O-glycan synthesis. The knockout population is generated without clonal selection, thereby preserving heterogeneous genomic edits and functional diversity, making it suitable for studying O-glycosylation and its roles in cancer biology. Researchers can expect a loss-of-function model for investigating downstream effects on mucin-type O-glycans and Tn antigen accumulation.
The parental SK-HEP-1 cell line originates from the ascitic fluid of a patient with liver adenocarcinoma and is classified as a hepatic adenocarcinoma epithelial cell line. Initially misidentified as hepatocellular carcinoma, SK-HEP-1 cells exhibit an endothelial/epithelial hybrid phenotype and serve as a widely utilized model for liver cancer biology, tumorigenesis, and drug metabolism studies. Their robust growth in vitro and tumorigenicity in vivo make them a versatile platform for dissecting molecular mechanisms underlying hepatic malignancy and for screening novel therapeutic agents. The SK-HEP-1 background provides a physiologically relevant context for studying aberrant glycosylation in liver-derived tumors, particularly given the liver??s central role in glycoprotein synthesis.
C1GALT1C1, also known as Cosmc, functions as a specific molecular chaperone that facilitates the proper folding and stability of C1GALT1, the T-synthase enzyme that catalyzes the formation of the core 1 O-glycan (Gal??1-3GalNAc-??-Ser/Thr). Loss of C1GALT1C1 leads to C1GALT1 degradation, truncation of O-glycans, and accumulation of the Tn antigen (GalNAc-??-Ser/Thr). This disruption impacts key signaling networks, including mucin-type O-glycosylation and integrin-mediated cell adhesion. Downstream targets include mucin-type O-glycoproteins such as MUC1 and MUC16, as well as integrins ITGA2 and ITGB1. The SP1 transcription factor acts as an upstream regulator, while C1GALT1 is the direct interacting client protein. Aberrant O-glycosylation caused by C1GALT1C1 loss alters interactions with galectin-3 and modulates UDP-galactose and UDP-GlcNAc utilization, ultimately affecting pathways related to cell adhesion, invasion, and tumor progression.
In the SK-HEP-1 hepatic adenocarcinoma context, knockout of C1GALT1C1 creates a powerful model for examining the role of O-glycosylation in liver cancer progression. The accumulation of Tn antigen, a well-known tumor-associated carbohydrate antigen, mimics glycosylation patterns observed in human hepatocellular carcinoma and adenocarcinomas. This model allows researchers to dissect how altered O-glycan structures influence tumor cell adhesion to extracellular matrix, migration, invasion, and metastatic potential. The polyclonal nature of the knockout population enables analysis of functional heterogeneity and selection dynamics under different experimental conditions, such as drug treatment or microenvironmental stress. By combining this model with transcriptomic or glycoproteomic approaches, investigators can identify novel glycosylation-dependent mediators of hepatic tumorigenesis and therapy resistance.
Typical research applications include quantitative analysis of Tn antigen expression using lectin blotting with VVL or PNA, flow cytometry, and immunofluorescence. This cell population is well-suited for functional assays evaluating cell migration, invasion, and adhesion to ECM substrates, as well as apoptosis assays to assess O-glycan-dependent survival signaling. The model can be applied to study glycosylation-targeted therapies, investigate the role of Cosmc in the tumor microenvironment, and facilitate biomarker discovery for cancer glycosylation. Knockout validation can be performed via western blot for C1GALT1 and sequencing, while RNA-seq can profile glycosylation-related gene expression changes. For in vivo studies, these cells are amenable to tumor xenograft metastasis models. For additional technical details or custom configurations, please contact Ascent Research.
